Search Results - "Lathia, Chetan D."

Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma by LLOVET, Josep M, PENA, Carol E. A, LATHIA, Chetan D, SHAN, Michael, MEINHARDT, Gerold, BRUIX, Jordi

“…Validated biomarkers of prognosis and response to drug have not been identified for patients with hepatocellular carcinoma (HCC). One of the objectives of the…”
Get full text

Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours by Awada, Ahmad, Hendlisz, Alain, Christensen, Olaf, Lathia, Chetan D, Bartholomeus, Sylvie, Lebrun, Fabienne, de Valeriola, Dominique, Brendel, Erich, Radtke, Martin, Delaunoit, Thierry, Piccart-Gebhart, Martine, Gil, Thierry

“…Abstract Aim The safety, pharmacokinetics and efficacy of sorafenib plus docetaxel in patients with advanced refractory cancer were investigated in a Phase I,…”
Get full text

Safety and Pharmacokinetics of Sorafenib Combined With Capecitabine in Patients With Advanced Solid Tumors: Results of a Phase 1 Trial by Awada, Ahmad, Gil, Thierry, Whenham, Nicolas, Van Hamme, Julie, Besse-Hammer, Tatiana, Brendel, Erich, Delesen, Heinz, Joosten, Miranda C., Lathia, Chetan D., Loembé, Bienvenu A., Piccart-Ghebart, Martine, Hendlisz, Alain

“…Sorafenib (twice daily [bid]) plus capecitabine (2 weeks on schedule/1 week off schedule) safety and pharmacokinetics were investigated in patients with…”
Get full text

Biomarkers and surrogate endpoints: how and when might they impact drug development? by Lathia, Chetan D

“…As the pharmaceutical industry starts developing novel molecules developed based on molecular biology principles and a better understanding of the human…”
Get full text

A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin by Molina, Julian R, Reid, Joel M, Erlichman, Charles, Sloan, Jeff A, Furth, Alfred, Safgren, Stephanie L, Lathia, Chetan D, Alberts, Steven R

“…Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that degrade the extracellular matrix during the processes of invasion, metastasis and…”
Get full text

Abstract SY11-02: Detection of tumor-associated mutations in circulating DNA: clinical applications and experiences by Jeffers, Michael, Lathia, Chetan D., Wilhelm, Scott M., Voliotis, Dimitris, Laurent, Dirk, Pena, Carol E.

“…Abstract The detection of tumor-associated mutations is of paramount importance in the era of personalized medicine. Mutational testing is now a prerequisite…”
Get full text

Evaluation of the PI3K inhibitor BAY 80-6946 in hematologic malignancies by Jeffers, Michael, Dubowy, Ronald L., Lathia, Chetan D., Mallon, Robert, Appleman, Leonard Joseph, Ramanathan, Ramesh K., Patnaik, Amita

“…Abstract only e13576 Background: BAY 80-6946 is a new investigational compound that potently inhibits all PI3K Class I isoforms. BAY 80-6946 is under phase 1…”
Get full text

A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors by SKLARIN, N. T, LATHIA, C. D, BENSON, L, GROVE, W. R, THOMAS, S, ROCA, J, EINZIG, A. I, WIERNIK, P. H

“…CI-980 is a synthetic mitotic inhibitor that binds to the colchicine binding site of tubulin. It demonstrates broad activity against human and murine tumor…”
Get full text

Abstract LB-295: Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenib vs placebo in TKI-refractory metastatic GIST by Demetri, George D., Jeffers, Michael, Reichardt, Peter, Kang, Yoon-Koo, Blay, Jean-Yves, Rutkowski, Piotr, Gelderblom, Hans, Hohenberger, Peter, Leahy, Michael, von Mehren, Margaret, Joensuu, Heikki, Badalamenti, Giuseppe, Blackstein, Martin, Le Cesne, Axel, Schöffski, Patrick, Maki, Robert G, Bauer, Sebastian, Bui Nguyen, Binh, Xu, Jianming, Nishida, Toshirou, Chung, John, Lathia, Chetan D., Kappeler, Christian, Kuss, Iris, Laurent, Dirk, Casali, Paolo G

“…Abstract Background: GRID is a phase III study for patients with advanced gastrointestinal stromal tumors (GIST) following failure of imatinib (I) and…”
Get full text

Abstract C124: Pharmacokinetics and safety of sorafenib in combination with capecitabine in advanced solid tumors by Infante, Jeffrey R., Jones, Suzanne F., Bendell, Johanna C., Greco, F. Anthony, Yardley, Denise A., Woudenberg, Janet, Lathia, Chetan D., Lane, Cassie M., Spigel, David R., Hainsworth, John D., Burris, Howard A.

“…Abstract Background: This study had two primary objectives: first to address a possible increase in capecitabine (C) exposure when co-administered with…”
Get full text

Biomarkers and surrogate endpoints: How and when might they impact drug development?: Surrogate endpoints in medicine by LATHIA, Chetan D

Get full text

Validated HPLC/MS/MS assay for CI-1011 in rat plasma and a comparison with an HPLC/UV assay by Bullen, William W., Lathia, Chetan D., Abel, Robert B., Hayes, Roger N.

“…A liquid chromatographic/mass spectrometric (LC/MS/MS) method to quantitate CI-1011 in rat plasma has been validated and compared to an LC/UV assay. The…”
Get full text

An HPLC assay utilizing solid-phase extraction for CI-1010, an alkylating radiosensitizer, in rat plasma by Bullen, William W., Rossi, David T., Hoffman, Keith L., Suri, Ajit, Lathia, Chetan D.

“…CI-1010, a 2-nitroimidazole, is a chiral prodrug for the active moiety PD 146923 and is under development as an alkylating radiosensitizer to be used as an…”
Get full text